Straightforward AAV manufacturing process scale up from bench-scale to 2000L STR
Webinar Date/Time: Mon, Dec 11, 2023 11:00 AM EST
Discuss the development and challenges of a highly scalable adeno-associated virus (AAV) manufacturing platform
Register Free: https://www.biopharminternational.com/bp_w/2000L
Event Overview:
Recombinantly produced adeno-associated viruses (AAV) are the predominant viral vectors used for in vivo gene therapies owing to their relatively good safety, long term transgene expression, ability to infect a broad range of cells and ease in achieving high titers at small-scale. One of the main challenges in bringing AAV-based therapies to patients, is the ability to efficiently translate bench-scale processes to commercial
GMP manufacturing while meeting the high dosage requirements. In this context, Polyplus, Exothera and Alexion collaborated for the development of a highly scalable AAV manufacturing platform with a capacity ranging from 1L to 200L and 2000L.
Key Learning Objectives:
- Developing scalable transfection process with DOE (Design of Experiments)
- Scaling-up while maintaining consistent transfection complex growth for efficient delivery to cells
Who Should Attend:
- Viral vector manufacturers
- Viral vector sponsors
- Pharma
- Biotech
Speakers:
Daniel Koback
Bioprocess Applications Specialist
Polypus
Daniel Koback holds a master’s degree in biomedical engineering from Worcester Polytechnic Institute. After several years of hands-on experience as senior associate scientist in Upstream Process Development working with rAAV gene therapy, mAbs, and vaccines, he joined Polyplus in 2022 as a Bioprocess Application Specialist.
Emilie Gateau
Innovation Manager
Exothera
Emilie Gateau holds a Master of Biotechnology and Food Science. She has over 6 years of experience in bioprocess development, with expertise in Quality by design & design of experiments experience, cell line development, upstream process scale-up experience, and mammalian cell culture process development for viral vectors and recombinant protein.
Register Free: https://www.biopharminternational.com/bp_w/2000L
Trump Directs FDA, EPA to Reduce Regulatory Barriers to Domestic Pharma Manufacturing
May 7th 2025The White House is instructing FDA to increase fees for and inspections of foreign drug manufacturing plants and reduce the time required to approve such sites that will be newly constructed in the US.
